How transparent are migraine clinical trials?

Repository of Registered Migraine Trials (RReMiT)

OPEN

Faustine L. Dufka, BA
Robert H. Dworkin, PhD
Michael C. Rowbotham,
MD

Correspondence to
Dr. Rowbotham:
rowbotm@cpmcni.org

ABSTRACT

Transparency in research requires public access to unbiased information prior to trial initiation and openly available results upon study completion. The Repository of Registered Migraine Trials is a global snapshot of registered migraine clinical trials and scorecard of results availability via the peer-reviewed literature, registry databases, and gray literature. The 295 unique clinical trials identified employed 447 investigational agents, with 30% of 154 acute migraine trials and 11% of 141 migraine prophylaxis trials testing combinations of agents. The most frequently studied categories in acute migraine trials were triptans, nonsteroidal anti-inflammatory drugs, antiemetics, calcitonin gene-related peptide antagonists, and acetaminophen. Migraine prophylaxis trials frequently studied anticonvulsants, β -blockers, complementary/alternative therapies, antidepressants, and botulinum toxin. Overall, 237 trials were eligible for a results search. Of 163 trials completed at least 12 months earlier, 57% had peer-reviewed literature results, and registries/gray literature added another 13%. Using logistic regression analysis, studies with a sample size below the median of 141 subjects were significantly less likely to have results, but the dominant factor associated with availability of results was time since study completion. In unadjusted models, trials registered on ClinicalTrials.gov and trials with industry primary sponsorship were significantly more likely to have results. Recently completed trials rarely have publicly available results; 2 years after completion, the peer-reviewed literature contains results for fewer than 60% of completed migraine trials. To avoid bias, evidence-based therapy algorithms should consider factors affecting results availability. As negative trials are less likely to be published, special caution should be exercised before recommending a therapy with a high proportion of missing trial results. *Neurology*® 2014;83:1372-1381

GLOSSARY

ACTION = Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks; **CI** = confidence interval; **CTG** = ClinicalTrials.gov; **FDA** = Food and Drug Administration; **FDAIA** = Food and Drug Administration Amendments Act of 2007; **ICMJE** = International Committee of Medical Journal Editors; **ICTRP** = International Clinical Trials Registry Platform; **NSAID** = nonsteroidal anti-inflammatory drugs; **OR** = odds ratio; **RReACT** = Repository of Registered Analgesic Clinical Trials; **RReMiT** = Repository of Registered Migraine Trials.

Migraine is a common neurologic disorder that produces significant disability and reduced health-related quality of life. Population-based surveys and longitudinal studies report migraine prevalence ranging from 16% to 23% (17% in women and 6% in men).¹⁻³ The WHO ranks migraine 19th in terms of years lived with disability.⁴ Epidemiologic studies suggest that episodes are frequent and severe enough to justify preventive therapy in 39% of migraineurs, but only 3%–13% use it.¹ Migraine therapy guidelines distinguish between treatment of acute migraine and migraine prevention.⁵⁻¹¹ Some acute therapy guidelines focus on specific clinical situations, such as treatment in the emergency department or use of opioid analgesics.^{12,13} Evidence-based guidelines typically combine systematic literature reviews, grading of the available research data, and expert opinion.

In this project, the science behind migraine therapy is approached from a different perspective. A snapshot of the entire landscape of migraine clinical trials and a scorecard of publicly available results for completed trials reveals how much progress has been made toward transparency in

From the California Pacific Medical Center Research Institute (F.L.D., M.C.R.), San Francisco; and the University of Rochester School of Medicine and Dentistry (R.H.D.), NY.

Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. The Article Processing Charge was paid by ACTION public-private partnership funds.

This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

research, i.e., the public can learn of the study before initiation and find results once the study is completed. The snapshot and scorecard approach assists guideline developers by estimating how much data are unavailable. The potential for bias in guidelines is reduced by determining study characteristics most strongly predicting availability of results.

The 1997 Food and Drug Administration (FDA) Modernization Act resulted in the creation of the ClinicalTrials.gov (CTG) registry,^{14,15} and the subsequent FDA Amendments Act of 2007 (FDAAA) requires all FDA phase 2–4 biologic drug and device trials be registered on CTG within 21 days of study start date.^{14,16} However, registration before subject enrollment commences is inconsistent in many areas of clinical research,^{17–20} and registry fields are often missing or incomplete.^{21–24}

Accessing results of completed trials is more difficult than accessing basic trial information. In 2005, the International Committee of Medical Journal Editors (ICMJE) set clinical trial registration as a precondition for publication in an ICMJE journal.²⁵ ICMJE guidelines are not always followed, and manuscripts reporting on unregistered studies can publish in one of the many journals not requiring preregistration.^{26,27} Concerns about low publication rates and the lag time between study completion and final journal publication persist.^{20,21,28–32} Publication bias, selective outcome reporting, and other types of reporting bias remain prevalent.^{14,17,18,33–39} Discrepancies between the registry trial record, conference abstract, and final published article are disturbingly common, and often favor statistically significant results.^{22,40,41} In the few instances where unpublished results are publicly available on the FDA's Web site, studies have demonstrated significantly altered efficacy estimates and risk/benefit ratios compared to the peer-reviewed literature.^{35,39,42–44}

In 2008, the CTG Web site was reconfigured to allow basic trial results to be uploaded in a tabulated format.³¹ No other large trial registry allows direct posting of study results. For certain categories of industry-sponsored trials, posting summarized results on CTG within 1 year of study completion, or within 30 days of FDA approval of the drug being studied, is a legal requirement.^{16,45} Compliance is poor; recent

studies have found that only 22% of clinical trials required to post study results on CTG met their reporting deadline,^{46,47} and only 28%–45% had results that could be found via CTG or PubMed.^{19,30,48} Fewer than 10% of completed trials provided both a linked article and basic results.³⁰ For those trials not required by the FDAAA mandate to post results, only 10% posted results within a year.⁴⁷

An important but often overlooked source of information about trial results is the gray literature of trial-specific press releases or company statements and information found on the public Web sites of pharmaceutical companies.^{49–51} Trials presented at scientific meetings may remain unpublished years after presentation, but meeting program abstracts can sometimes be found by searching the Internet. However, results in the gray literature are not permanent, are not indexed on PubMed, may differ greatly from the actual meeting posters, and are not likely to have been fully peer-reviewed.^{50,52} Overall, results in the gray literature have smaller treatment effects than results in the published literature, suggesting that some negative trials reported in the gray literature do not progress to full journal publication.^{39,51,53}

METHODS Developed as part of the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public–private partnership, the Repository of Registered Migraine Trials (RReMiT) provides a snapshot of registered clinical trials for migraine and a scorecard for public availability of results. The WHO International Clinical Trials Registry Platform (ICTRP) provides a single public-access search portal to 15 primary registries, which all follow the international standards for clinical trial registries based on ICMJE requirements.^{25,52,54,55}

RReMiT follows methodology initially developed for the Repository of Registered Analgesic Clinical Trials (RReACT), which comprises all analgesic clinical trials for postherpetic neuralgia, fibromyalgia, and diabetic peripheral neuropathy.^{52,56} Both RReMiT and RReACT are freely accessible via the ACTTION Web site (<http://www.acttion.org/>).

We searched all ICTRP primary registries to identify trials of acute migraine treatment and migraine prophylaxis. Trials in RReMiT are randomized, and have a primary (or key secondary) outcome measure assessing drug efficacy. Trials of nutritional supplements and nontraditional medications are included, but device studies are excluded. RReMiT provides registry information on investigational drug names, drug route and mechanism of action, secondary identifiers, study sponsor, study phase, start and completion dates, countries of enrollment, number of subjects, design summary, comparison groups, and primary/key secondary outcomes. Trial status (as of August 2013) is listed as actively recruiting, active but not recruiting, terminated, completed, unknown, or other.

All trials found were examined manually. If the same trial was listed on 2 or more registries, it was considered to be multiply

registered and only analyzed once, as in RReACT.⁵² Results were sought except for those trials shown as actively recruiting, withdrawn prior to subject enrollment, or not yet open for recruitment. A comprehensive search algorithm was followed. If links or citations of journal publications were provided on the registry record, they were manually checked to confirm correct pairing with the registered trial. If none was available, a manual search of PubMed using the trial name, drug name, keywords from the study title, registry identifiers, and other trial information was conducted. The gray literature was searched using Google, Google Scholar, and sponsor-related Web sites. To ensure accurate registry–results pairings, we relied on all available trial information, including registry data on comparison groups, sample size, principal investigator, and study dates. Available trial-specific efficacy endpoint results are categorized as peer-reviewed journal article, data entered on registry, or gray literature. Results from the highest-level source are summarized, with peer-reviewed articles ranking highest and gray literature lowest.

We first categorized each trial as testing acute migraine therapy or migraine prophylaxis. We then determined whether the treatment consisted of a single therapeutic agent or a combination of agents (defined as treatments consisting of multiple agents

administered separately in one or more study arms, as well as single pills/capsules containing multiple active ingredients such as the Treximet combination of sumatriptan and naproxen). We also determined whether the trial design included a true placebo group. Active comparators were not considered true placebos and were included as investigational agents. Placebo arms providing rescue medications to patients as needed were considered true placebo groups.

Each investigational agent was categorized into only 1 of 22 predetermined classes (table 1). Drugs with multiple effects or uses were classified based on their most relevant effect. Agents not falling into any of the predetermined classes were categorized as other. Some categories were broadly defined to accommodate investigational agents with multiple effects, those under study for off-label use in migraine, and those with unknown mechanisms of action. For example, the anticonvulsant category included AMPA/kainate antagonists, not yet approved for sale as anticonvulsants, and tonabersat, a benzopyran derivative with anticonvulsant properties (table 1). The other category included agents ranging from barbiturates to renin-angiotensin system inhibitors and nontriptan drugs acting on 5HT receptor subtypes other than 1B/1D. Cannabinoids were categorized as complementary/alternative therapy because preparations containing the active

Table 1 Categories of investigational agents in RReMiT migraine trials

Category	Investigational agents included
Acetaminophen	Acetaminophen, paracetamol
Adenosine receptor antagonist	Caffeine
Anticonvulsant	BGG492, carisbamate, divalproex sodium, eslicarbazepine acetate, ethosuximide, flunarizine, gabapentin, lacosamide, perampanel, pregabalin, sodium valproate, tezampand, tonabersat, topiramate, zonisamide
Antidepressant	Amitriptyline, duloxetine, milnacipran, nortriptyline, sertraline
Antiemetic	Domperidone, granisetron, metoclopramide, prochlorperazine, promethazine
Antihistamine	Betahistine, diphenhydramine, pizotifen
β-Blocker	Metoprolol, nadolol, propranolol
Botulinum toxin	Botulinum toxin A (Botox)
Calcitonin gene-related peptide antagonist	ALD403, AMG 334, BI 44370, BMS-927711, LY2951742, MK-1602, MK-3207, telcagepant (MK-0974)
Calcium channel blocker	Cinnarizine, verapamil
Complementary/alternative therapy	Acetyl-L-carnitine, Amigra (botanical drug product), carbon dioxide, <i>Coriandrum sativum</i> , Dronabinol (δ-9-tetrahydrocannabinol), folate (vitamin D ₉), <i>Ginkgo biloba</i> extract, Huo Xue Shu Feng grain (Chinese traditional medicine), magnesium oxide, Mahavat Vidhwansan Ras (ayurvedic medicine), Migra-Zen Relief Plus (herbal dietary supplement), Migravent (combination of riboflavin, magnesium, coenzyme Q10), normobaric oxygen, Palsinuron (Ayurvedic medicine), riboflavin (vitamin B ₂), saline, Serkangabin (Iranian traditional medicine), vitamin B ₁₂ , vitamin D
Corticosteroid	Acthar, dexamethasone, methylprednisolone, triamcinolone
EP4 receptor antagonist	BGC20-1531
Ergot alkaloids	Ergotamine, MAP0004
Hormone therapy	Estrogen, melatonin, octreotide, oxytocin, Seasonique
Hypnotic	Eszopiclone, midazolam, propofol, ramelteon
Nerve block/local anesthetic application	Bupivacaine, Diprofos, lidocaine, ropivacaine
Nitric oxide synthase inhibitor	GW274150, NXN-188
NSAID/aspirin	Aspirin, dexketoprofen, diclofenac, ibuprofen, ketoprofen, ketorolac, lornoxicam, naproxen, nimesulide
Opioid	Tramadol
Triptan	Almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan
Other	ADX10059, aliskiren, bismuth subcitrate, butalbital, candesartan, clopidogrel, COL-144, cyclobenzaprine, donepezil, doxycycline, enalapril, ibudilast, isovaleramide, ketamine, loxapine, LY2300559, LY2590443, metronidazole, MK-6096, N-α methyl histamine, olanzapine, omeprazole, picotamide, pituitary adenylate cyclase-activating polypeptide-38, SB-705498, simvastatin, tetracycline, vasoactive intestinal polypeptide

Abbreviations: NSAID = nonsteroidal anti-inflammatory drugs; RReMiT = Repository of Registered Migraine Trials.

ingredients vary across states and countries in type, availability, and legal status.

Logistic regression analysis was used to identify factors associated with availability of trial results. Initially, univariate models examined the following variables: trial registration on CTG (yes vs no), industry primary sponsor (yes vs no), time since study completion (2 years or more vs less than 2 years from August 2013 based on the registry-listed completion date), type of therapy (acute vs prophylaxis), treatment type (single investigational agent vs combination), presence of a true placebo group (yes vs no), and estimated sample size (dichotomized above vs below the median). Availability of any results (peer-reviewed, registry, or gray literature), and availability of results in the peer-reviewed literature, were analyzed separately.

The variables that showed significant, or nearly significant ($p < 0.1$), relationships in univariate analyses were included in the final logistic regression models, and adjusted odds ratios (ORs) were generated for 2 outcomes: availability of any results and availability of peer-reviewed results.

RESULTS Trial registration. As of August 1, 2013, there were 295 unique clinical trials meeting criteria for inclusion in the RReMiT database on the 15 primary ICTRP registries. A total of 215 trials were registered on CTG. The other 80 trials were listed exclusively on one or more of ICTRP's 14 other registries. Forty-one trials were multiply registered, with

Figure Number of trials initiated over time, with trial status and results availability

(A) The number of new trials initiated each year for both acute migraine trials and migraine prophylaxis trials. (B) The trends over time for the cumulative total number of trials, the cumulative number of trials eligible for a results search (total number of trials minus those actively recruiting, those withdrawn prior to subject enrollment, and those not yet open for recruitment), the cumulative number of trials with results available of any type (peer-reviewed literature, results entered on registry, and gray literature), and the cumulative number of trials with results available in the peer-reviewed literature.

32 trials on both CTG and EU Clinical Trials Register, 2 on 3 different registries, and 7 on other pairs of registries. The median estimated sample size was 141 subjects.

The RReMiT database contains 154 (52%) acute migraine treatment trials and 141 (48%) migraine prophylaxis trials. The figure, A, shows the number of registered trials initiated each year for the past 15 years. The year 2009 had the most trial initiations. More migraine prophylaxis trials were initiated in the last 5 years (2009–2013) than in the previous 5 years (2004–2008), a temporal association not present in acute migraine treatment trials (Fisher exact test; $p = 0.014$).

Investigational agents. A total of 447 investigational agents were used in the 295 RReMiT trials. The most frequently studied categories were triptans (34% of all 295 trials), anticonvulsants (22%), nonsteroidal anti-inflammatory drugs (NSAID) (15%), other (10%), complementary/alternative therapies (8%), β -blockers (7%), and antiemetics (7%). Combination treatments

were used in 61 trials (21%). Thirteen trials compared different triptans, and 9 trials compared agents within another single category. The design of 177 trials (60%) included a true placebo group.

The most frequently studied categories of investigational agents in the 154 acute migraine treatment trials were triptans (58%), NSAID (26%), antiemetics (12%), calcitonin gene-related peptide antagonists (8%), other (8%), and acetaminophen (6%) (table 2). Thirty percent of all acute migraine trials (46/154) tested combinations of agents and 57% (88/154) included a true placebo group.

The most frequently studied categories in the 141 migraine prophylaxis trials were anticonvulsants (40%), β -blockers (13%), complementary/alternative therapies (13%), other (12%), antidepressants (10%), and botulinum toxin (8%) (table 2). Eleven percent of all migraine prophylaxis trials (15/141) evaluated combinations of agents and 63% (89/141) included a true placebo group.

Table 2 Frequency of investigational agents studied for acute migraine trials and migraine prophylaxis trials

Investigational agent	Acute trials		Prophylaxis trials	
	No. (%) of trials	No. (%) of agents	No. (%) of trials	No. (%) of agents
Acetaminophen	10 (6)	10 (4)	1 (<1)	1 (<1)
Adenosine receptor antagonist	7 (5)	7 (3)	—	—
Anticonvulsant	7 (5)	7 (3)	57 (40)	61 (31)
Antidepressant	—	—	14 (10)	14 (7)
Antiemetic	19 (12)	21 (8)	1 (<1)	1 (<1)
Antihistamine	4 (3)	4 (2)	2 (1)	2 (1)
β -Blocker	1 (<1)	1 (<1)	19 (13)	19 (10)
Botulinum toxin	—	—	11 (8)	11 (6)
Calcitonin gene-related peptide antagonist	12 (8)	12 (5)	5 (4)	5 (3)
Calcium channel blocker	—	—	5 (4)	5 (3)
Complementary/alternative therapy	6 (4)	6 (2)	19 (13)	19 (10)
Corticosteroid	7 (5)	7 (3)	3 (2)	3 (2)
EP4 receptor antagonist	1 (<1)	1 (<1)	1 (<1)	1 (<1)
Ergot alkaloids	1 (<1)	1 (<1)	1 (<1)	1 (<1)
Hormone therapy	2 (1)	2 (<1)	6 (4)	6 (3)
Hypnotic	5 (3)	5 (2)	4 (3)	4 (2)
Nerve block/local anesthetic application	7 (5)	6 (2)	3 (2)	4 (2)
Nitric oxide synthase inhibitor	4 (3)	4 (2)	1 (<1)	1 (<1)
NSAID/aspirin	40 (26)	40 (16)	5 (4)	4 (2)
Opioid	1 (<1)	1 (<1)	—	—
Triptan	89 (58)	105 (42)	10 (7)	10 (5)
Other	12 (8)	12 (5)	17 (12)	21 (11)
Total	154	253	141	194

Abbreviation: NSAID = nonsteroidal anti-inflammatory drugs.

Table 3 Trial status, availability of results, and results type

	All trials	Acute trials	Prophylaxis trials
Total trials	295	154	141
No. completed	200	119	81
No. terminated or unknown	34	17	17
No. active, not recruiting	18	7	11
No. recruiting	43	11	32
No. total results	131	81	50
No. results in peer-reviewed literature	106	64	42
No. results entered on registry	15	9	6
No. results in gray literature only	10	8	2

Trial status and availability of trial results. Forty-three of the 295 total trials were actively recruiting participants, 7 were withdrawn prior to subject enrollment, and 8 were not yet open for recruitment. Results were sought for the remaining 237 trials (200 trials listed as completed, 13 trials terminated after beginning enrollment, 10 trials listed as active but not recruiting, and 14 trials of unknown status). Table 3 and the figure, B, describe trials by status and trends over time. Except for 2 studies of unknown status, all studies initiated in 2006 or earlier have been completed or terminated. All studies listed as actively recruiting were initiated in 2008 or later.

Fifty-five percent of trials (131/237) had available results. By manually searching PubMed, 45% (106/237) had results in a peer-reviewed journal. Another 15 had results available via direct posting on the registry (all on CTG), and 10 had results available only in the gray literature. Focusing only on the 200 trials listed as completed, results could be found for 127 (64%), 103 (52%) of which were in peer-reviewed journals, 15 were posted directly onto the registry, and 9 were in the gray literature.

Most, but not all, studies listed as completed provide a completion date. Of 163 trials with a listed completion date of August 2012 or before, 57% had peer-reviewed literature results, and registries/gray literature added another 13%. In contrast, 14 trials in RReMiT listed a completion date between August 2012 and August 2013, and none had available results. For the 147 trials with a listed completion date of August 2011 or before, 59% had peer-reviewed literature results (71% with any available results). Only 20% of the 30 trials with listed completion dates between August 2011 and August 2013 had peer-reviewed publications (30% with any available results). For those trials with article links on the registry trial record, the average number of linked publications was 1.35.

Correlates of results availability. Factors in the univariate analyses predicting results availability (peer-reviewed literature, results deposited on the registry, and gray literature) included trial registration on CTG ($p = 0.004$), industry primary sponsor ($p < 0.001$), and time since study completion of 2 years or more ($p < 0.001$) (table 4). Study enrollment below the median

Table 4 Factors related to the availability of peer-reviewed results and results of any type (peer-reviewed literature, results deposited on registry, and gray literature) in unadjusted models

	Peer-reviewed results, OR (95% CI)	Any type of results, OR (95% CI)
Trial registration on CTG ^a (vs not registered on CTG)	1.8 (1.0–3.4)	2.4 (1.3–4.4)
Industry primary sponsor ^b (vs no industry or industry secondary sponsorship)	2.0 (1.2–3.4)	3.1 (1.8–5.4)
Time since study completion 2 years or more ^c (vs less than 2 years)	7.7 (3.1–19.2)	6.6 (3.0–14.2)
Acute treatment ^a (vs prophylaxis)	1.2 (0.7–2.1)	1.5 (0.9–2.5)
Single investigational agent ^a (vs combination of agents)	0.7 (0.4–1.4)	0.8 (0.4–1.4)
True placebo group ^d (vs no placebo group)	1.0 (0.6–1.7)	1.3 (0.8–2.2)
Enrollment below median sample size ^e (vs above median)	0.5 (0.3–0.8)	0.3 (0.2–0.6)

Abbreviations: CI = confidence interval; CTG = ClinicalTrials.gov; OR = odds ratio.

^aAll trials eligible for a results search ($n = 237$).

^bAll trials eligible for a results search that indicated sponsor information on the registry ($n = 236$).

^cAll trials eligible for a results search that indicated a completion date on the registry preceding the data collection (before August 2013) ($n = 208$).

^dAll trials eligible for a results search, excluding the 3 trials where we were unable to determine whether the trial included a true placebo arm ($n = 234$).

^eAll trials eligible for a results search that indicated estimated sample size on the registry ($n = 234$).

sample size negatively predicted results availability in the unadjusted model ($p < 0.001$).

When considering the availability of peer-reviewed publications, the same variables significantly, or nearly significantly, predicted results availability in unadjusted models: trial registration on CTG ($p = 0.055$), industry primary sponsor ($p = 0.011$), and time since study completion of 2 years or more ($p < 0.001$) (table 4). Examining the data by specific time epochs (≥ 2 years but < 4 years, ≥ 4 years but < 6 years, ≥ 6 years but < 8 years, and ≥ 8 years) showed steadily increasing unadjusted ORs of 4.6, 7.5, 8.6, and 14.6 relative to completion less than 2 years ago. Study enrollment below the median sample size negatively predicted availability of peer-reviewed results ($p = 0.007$).

Variables not predicting results availability, including in peer-reviewed publications, were the type of therapy (acute vs prophylaxis), treatment type (single investigational agent vs combination), and presence of a true placebo group.

In the multivariate analysis, 2 factors predicted results availability (table 5). Studies completed 2 or more years ago were significantly more likely to have available results (adjusted OR 4.5, 95% confidence interval [CI] 2.0–10.5; for peer-reviewed publications, adjusted OR 6.9, 95% CI 2.6–18.2). Trials with a sample size below the median of 141 subjects were significantly less likely to have available results (adjusted OR 0.4, 95% CI 0.2–0.8).

DISCUSSION RReMiT presents a complete and global picture of all registered acute migraine treatment trials and migraine prophylaxis trials contained in the 15 ICTRP registries, including the largest, ClinicalTrials.gov. As with RReACT,⁵² successfully building RReMiT required extensive manual searching and verification at several points. First, the registries had to be searched with a variety of techniques to find all relevant trials. Second, each registry record had to be examined individually to ensure that only unique trials were

analyzed; registries are not consistently cross-linked and some trials were listed on up to 3 different registries. Third, a complex search strategy was employed to find results outside the peer-reviewed literature. Although the gray literature contributed a relatively small number of results in RReMiT compared to RReACT (4.2% vs 8.7% of trials had results only in the gray literature), and gray literature results are not necessarily permanently archived or peer-reviewed, this is an important resource that cannot be overlooked.

Eleven ICTRP registries allow linking of the registry record to a publication. However, links are often not provided, even on CTG. A study by Huser and Cimino⁵⁷ found that 44% of trials without linked results have published articles retrievable by manually searching PubMed. A different group reported that only 14% of a sample of trials on CTG had a published article linked to the registry record, and manually searching PubMed increased the proportion to 52%.³¹ Only 20% of trials in the RReMiT database had one or more published articles linked to the trial record, but this proportion increased to 45% when PubMed was manually searched. For those trials with article links, the average number of publications was 1.35, which is comparable to the value of 1.46 linked articles per trial calculated by Huser and Cimino³⁰ when analyzing a sample of trials registered on CTG. Accuracy and relevance of links cannot be assumed. Articles may not provide any results from the trial they are linked to, may reveal major protocol and subject enrollment differences from the registry description, may provide only preliminary/interim results, or may present only a pooled analysis of multiple trials.

The RReMiT database has limitations. First, unregistered trials are not included, but as adoption of trial registration has become progressively more widespread, the number of newly published results from unregistered trials should steadily decline.²⁶ Confirming that a published study is registered usually requires a manual search because 40%–45% of journal publications

Table 5 Adjusted likelihood for availability of peer-reviewed results and results of any type (peer-reviewed literature, results deposited on registry, and gray literature)^a

	Peer-reviewed results, OR (95% CI) ^b	Any type of results, OR (95% CI) ^b
Trial registration on CTG (vs not)	0.8 (0.3–1.9)	1.1 (0.5–2.6)
Industry primary sponsor (vs no industry or industry secondary sponsorship)	1.0 (0.4–2.1)	1.3 (0.6–3.0)
Time since study completion 2 years or more (vs less than 2 years)	6.9 (2.6–18.2)	4.5 (2.0–10.5)
Enrollment below median sample size (vs above median)	0.5 (0.2–1.0)	0.4 (0.2–0.8)

Abbreviations: CI = confidence interval; CTG = ClinicalTrials.gov; OR = odds ratio.

^aStudies included in the multivariate logistic regression model were limited to the trials that were eligible for a results search and indicated a completion date, sample size, and sponsor information on the registry ($n = 206$).

^bLogistic regression model included the following covariates: study registration on CTG, industry primary sponsor, time since study completion, and study enrollment.

fail to include trial registration numbers.⁵⁸ Many journals do not ask for specific trial registration numbers, and not all editors and publishers are convinced they should follow ICMJE guidelines.^{27,59} Finding relevant publications would be facilitated if journal publications always included trial registration numbers.

Furthermore, RReMiT does not calculate the exact time from study completion to availability of results for each trial, and therefore cannot assess compliance with the 2007 FDAAA mandate about reporting results within specified time periods. In other studies, as few as 12% of all trials had reported results within 1 year of study completion.²⁰ Ross et al.³² calculated 23 months as the median time to publication. In a random sample of 150 trials registered on CTG with results posted on the registry, Zarin et al.³¹ found the proportion with an associated peer-reviewed journal article had risen from 25% to 52% 1 year later. In RReMiT, 59% of trials completed at least 2 years ago had peer-reviewed publications available, compared to 20% of trials completed less than 2 years ago. There was no clear temporal break point, as the unadjusted OR steadily increased in each subsequent 2-year epoch since completion.

Does the responsibility for failing to publish fall on the authors or the system? Currently, for studies without available results, there are no methods short of individually asking every investigator if a results paper was ever submitted. It is unfortunate but well-known that negative trials are less likely to be published.⁶⁰ Competing articles whose findings are deemed more relevant for the readership are chosen instead to fill the limited pages of a journal. A funder may want to delay or prevent publication, or a manuscript may cycle through multiple journals over the course of a year before acceptance. For small studies with negative results, concerns over methods and power loom especially large since there is a difference between failing to reject the null hypothesis that there is no difference between groups and accepting the null hypothesis that there is no difference between groups. Although RReMiT does not interpret studies as positive or negative, it does show that studies with small sample sizes are less likely to have available results.

Perhaps contrary to expectations, industry primary sponsorship was positively associated with availability of results in univariate analyses. Other recent analyses of results and outcome reporting have also found that industry-funded trials were significantly more likely to have results deposited in the CTG registry.^{19,48} Law et al.²⁰ and Kuehn⁴⁶ reported that industry-sponsored clinical trials were more than 3 times more likely to post results on CTG than NIH-funded trials. A possible explanation is that industry-sponsored trials are in fact subject to higher public scrutiny and more institutional regulations, and

also may have more resources available to comply with reporting mandates.

By searching all the major clinical trial registries and analyzing nearly 300 migraine studies, the RReMiT database is an important contribution to the literature on trial registration and transparency in reporting of results. Compared with other disorders, are migraine trials more or less likely to have available results? In a recent update of the RReACT database for fibromyalgia, postherpetic neuralgia, and painful diabetic neuropathy trials, results of any kind could be found for 46% of the 391 trials eligible for a results search, and peer-reviewed publications could be found for 30% of trials, irrespective of time since completion.⁵² Migraine trials appear to be significantly better reported (55% with any results; 45% with peer-reviewed results; χ^2 test $p < 0.001$ for peer-reviewed results).

The peer-reviewed literature is an imperfect and incomplete resource for constructing evidence-based therapy guidelines. Biased recommendations could result if the published literature does not accurately reflect the full range of potentially available results. Even for large, well-designed drug registration trials, studies with negative results are much less likely to be published.⁴² In the case where a guidelines group was intending to recommend a drug as beneficial, many unavailable results from completed trials should reduce confidence in the recommendation on the grounds that the missing publications are more likely negative than positive. In the context of a global focus on clinical trials, complete transparency remains elusive. Forty percent of migraine trials remain unpublished more than 2 years following study completion. RReMiT demonstrates that recently completed studies, small studies, and studies without industry as the primary sponsor are all less likely to have results available in the peer-reviewed literature.

AUTHOR CONTRIBUTIONS

F.L. Dufka: lead on literature search, data collection, data analysis, initial draft of the manuscript, and figures and tables; contributed equally with Dr. Rowbotham on study design, data interpretation, and writing. Dr. Dworkin: contributed to study design, data analysis, data interpretation, and revisions of multiple drafts of the manuscript. Dr. Rowbotham: co-lead on study design, data interpretation, and writing; contributed to literature search, figures and tables, data collection, and data analysis.

ACKNOWLEDGMENT

The authors thank Dr. Peggy Cawthon, California Pacific Medical Center Research Institute, San Francisco Coordinating Center, for assistance with statistical analyses and performing a critical review of the manuscript.

STUDY FUNDING

Supported by a research subaward from FDA U101 FD004187-02 to University of Rochester, R Dworkin PI, Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership with the US Food and Drug Administration. The study sponsor had no role in study design; collection, analysis, and interpretation of data; writing of the report; or decision to submit the paper for publication.

DISCLOSURE

F. Dufka reports a grant from University of Rochester, US Food and Drug Administration, during the conduct of the study. R. Dworkin reports grants from University of Rochester, US Food and Drug Administration, during the conduct of the study. M. Rowbotham reports a grant from University of Rochester, US Food and Drug Administration, during the conduct of the study. Go to Neurology.org for full disclosures.

Received March 20, 2014. Accepted in final form July 10, 2014.

REFERENCES

1. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF; The American Migraine Prevalence and Prevention Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. *Neurology* 2007; 68:343–349.
2. Merikangas KR. Contributions of epidemiology to our understanding of migraine. *Headache* 2013;53:230–246.
3. Smitherman TA, Burch R, Sheikh H, Loder E. The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies. *Headache* 2013;53: 427–436.
4. Leonardi M, Steiner T, Scher A, Lipton RB. The global burden of migraine: measuring disability in headache disorders with WHO's classification of functioning, disability, and health (ICF). *J Headache Pain* 2005;6:429–440.
5. Worthington I, Pringsheim T, Gawel MJ, et al; Canadian Headache Society Acute Migraine Treatment Guideline Development Group. Canadian Headache Society guideline: acute drug therapy for migraine headache. *Can J Neurol Sci* 2013;40(5 suppl 3):S1–S80.
6. Pringsheim T, Davenport W, Mackie G, et al; Canadian Headache Society Prophylactic Guidelines Development Group. Canadian Headache Society guideline for migraine prophylaxis. *Can J Neurol Sci* 2012;39(suppl 2):S1–S59.
7. Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. *Neurology* 2012;78: 1346–1353.
8. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. *Neurology* 2012; 78:1337–1345.
9. Kelley NE, Tepper DE. Rescue therapy for acute migraine, part 1: triptans, dihydroergotamine, and magnesium. *Headache* 2012;52:114–128.
10. Kelley NE, Tepper DE. Rescue therapy for acute migraine, part 2: neuroleptics, antihistamines, and others. *Headache* 2012;52:292–306.
11. Kelley NE, Tepper DE. Rescue therapy for acute migraine, part 3: opioids, NSAIDs, steroids, and post-discharge medications. *Headache* 2012;52:467–482.
12. Colman I, Rothney A, Wright SC, Zilkalns B, Rowe BH. Use of narcotic analgesics in the emergency department treatment of migraine headache. *Neurology* 2004;62:1695–1700.
13. Gelfand AA, Goadsby PJ. A neurologist's guide to acute migraine therapy in the emergency room. *Neurohospitalist* 2012;2:51–59.
14. Zarin DA, Tse T. Medicine: moving toward transparency of clinical trials. *Science* 2008;319:1340–1342.
15. Food and Drug Administration Modernization Act of 1997. US Public Law No. 105–115 § 113.
16. Food and Drug Administration Amendments Act of 2007. Title VIII: Clinical Trials Databases, Section 801. 110th Congress Public Law 85. DOCID: f:publ085.110 [Internet]. 2007. Available at: <http://www.gpo.gov/fdsys/pkg/PLAW-110publ85/html/PLAW-110publ85.htm>. Accessed August 23, 2013.
17. Mathieu S, Boutron I, Moher D, Altman DG, Ravaud P. Comparison of registered and published primary outcomes in randomized controlled trials. *JAMA* 2009;302:977–984.
18. Strech D. Normative arguments and new solutions for the unbiased registration and publication of clinical trials. *J Clin Epidemiol* 2012;65:276–281.
19. Gill CJ. How often do US-based human subjects research studies register on time, and how often do they post their results? A statistical analysis of the ClinicalTrials.gov database. *BMJ Open* 2012;2:e001186.
20. Law MR, Kawasumi Y, Morgan SG. Despite law, fewer than one in eight completed studies of drugs and biologics are reported on time on ClinicalTrials.gov. *Health Aff* 2011; 30:2338–2345.
21. Ross JS, Mulvey GK, Hines EM, Nissen SE, Krumholz HM. Trial publication after registration in ClinicalTrials.gov: a cross-sectional analysis. *PLoS Med* 2009;6:1–9.
22. Dwan K, Altman DG, Cresswell L, Blundell M, Gamble CL, Williamson PR. Comparison of protocols and registry entries to published reports for randomised controlled trials. *Cochrane Database Syst Rev* 2011;MR000031.
23. Viergever RF, Gherzi D. The quality of registration of clinical trials. *PLoS One* 2011;6:e14701.
24. Viergever RF, Karam G, Reis A, Gherzi D. The quality of registration of clinical trials: still a problem. *PLoS One* 2014;9:e84727.
25. De Angelis C, Drazen JM, Frizelle FA, et al; International Committee of Medical Journal Editors. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. *N Engl J Med* 2004;351:1250–1251.
26. Huser V, Cimino JJ. Evaluating adherence to the International Committee of Medical Journal Editors' policy of mandatory, timely clinical trial registration. *J Am Med Inform Assoc* 2013;20:e169–e174.
27. Wager E, Williams P; Project Overcome Failure to Publish Negative Findings Consortium. "Hardly worth the effort"? Medical journals' policies and their editors' and publishers' views on trial registration and publication bias: quantitative and qualitative study. *BMJ* 2013;347:f5248.
28. Nguyen TA, Dechartres A, Belgherbi S, Ravaud P. Public availability of results of trials assessing cancer drugs in the United States. *J Clin Oncol* 2013;31:2998–3003.
29. Jones CW, Handler L, Crowell KE, Keil LG, Weaver MA, Platts-Mills TF. Non-publication of large randomized clinical trials: cross sectional analysis. *BMJ* 2013;347:f6104.
30. Huser V, Cimino JJ. Linking ClinicalTrials.gov and PubMed to track results of interventional human clinical trials. *PLoS One* 2013;8:e68409.
31. Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The ClinicalTrials.gov results database: update and key issues. *N Engl J Med* 2011;364:852–860.

32. Ross JS, Tse T, Zarin DA, Xu H, Zhou L, Krumholz HM. Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis. *BMJ* 2012;344:d7292.
33. McGauran N, Wieseler B, Kreis J, Schüler YB, Kölsch H, Kaiser T. Reporting bias in medical research: a narrative review. *Trials* 2010;11:37.
34. Rowbotham MC. The impact of selective publication on clinical research in pain. *Pain* 2008;140:401–404.
35. Turner EH, Knoopfelmacher D, Shapley L. Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database. *PLoS Med* 2012;9:e1001189.
36. Song F, Parekh S, Hooper L, et al. Dissemination and publication of research findings: an updated review of related biases. *Health Technol Assess* 2010;14:iii, ix–xi, 1–193.
37. Suñé P, Suñé JM, Montoro JB. Positive outcomes influence the rate and time to publication, but not the impact factor of publications of clinical trial results. *PLoS One* 2013;8:e54583.
38. Rising K, Bacchetti P, Bero L. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. *PLoS Med* 2008;5:e217; discussion e217.
39. Vedula SS, Bero L, Scherer RW, Dickersin K. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. *N Engl J Med* 2009;361:1963–1971.
40. Toma M, McAlister FA, Bialy L, Adams D, Vandermeer B, Armstrong PW. Transition from meeting abstract to full-length journal article for randomized controlled trials. *JAMA* 2006;295:1281–1287.
41. Smith SM, Wang AT, Pereira A, et al. Discrepancies between registered and published primary outcome specifications in analgesic trials: ACTTION systematic review and recommendations. *Pain* 2013;154:2769–2774.
42. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. *N Engl J Med* 2008;358:252–260.
43. Hart B, Lundh A, Bero L. Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses. *BMJ* 2012;344:d7202.
44. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. *Lancet* 2004;363:1341–1345.
45. Tse T, Williams RJ, Zarin DA. Reporting “basic results” in ClinicalTrials.gov. *Chest* 2009;136:295–303.
46. Kuehn BM. Few studies reporting results at US government clinical trials site. *JAMA* 2012;307:651–653.
47. Prayle AP, Hurley MN, Smyth AR. Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study. *BMJ* 2012;344:d7373.
48. Kirillova O. Results and outcome reporting in ClinicalTrials.gov, what makes it happen? *PLoS One* 2012;7:e37847.
49. Wieseler B, Kerekes MF, Vervoeelgyi V, McGauran N, Kaiser T. Impact of document type on reporting quality of clinical drug trials: a comparison of registry reports, clinical study reports, and journal publications. *BMJ* 2012;344:d8141.
50. Golder S, Loke YK, Bland M. Unpublished data can be of value in systematic reviews of adverse effects: methodological overview. *J Clin Epidemiol* 2010;63:1071–1081.
51. Hopewell S, McDonald S, Clarke MJ, Egger M. Grey literature in meta-analyses of randomized trials of health care interventions. *Cochrane Database Syst Rev* 2007;MR000010. Available at: <http://dx.doi.org/10.1002/14651858.MR000010.pub3>. Accessed May 23, 2014.
52. Munch T, Dufka FL, Greene K, Smith SM, Dworkin RH, Rowbotham MC. RReACT goes global: perils and pitfalls of constructing a global open-access database of registered analgesic clinical trials and trial results. *Pain* 2014;155:1313–1317.
53. Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K. Publication bias in clinical trials due to statistical significance or direction of trial results. *Cochrane Database Syst Rev* 2009;MR000006. Available at: <http://dx.doi.org/10.1002/14651858.MR000006.pub3>. Accessed May 23, 2014.
54. World Health Organization. International Standards for Clinical Trial Registries [Internet]. 2012. Available at: http://apps.who.int/iris/bitstream/10665/76705/1/9789241504294_eng.pdf. Accessed May 23, 2014.
55. The WHO Registry Network. About Registries: WHO Registry Criteria (version 2.1, April 2009) [Internet]. 2013. Available at: http://www.who.int/ictrp/network/criteria_summary/en/index.html. Accessed August 23, 2013.
56. Greene K, Dworkin RH, Rowbotham MC. A snapshot and scorecard for analgesic clinical trials for chronic pain: the RReACT database. *Pain* 2012;153:1794–1797.
57. Huser V, Cimino JJ. Precision and negative predictive value of links between ClinicalTrials.gov and PubMed. *AMIA Annu Symp Proc* 2012;2012:400–408.
58. van de Wetering FT, Scholten RJ, Haring T, Clarke M, Hoof L. Trial registration numbers are underreported in biomedical publications. *PLoS One* 2012;7:e49599.
59. Knüppel H, Metz C, Meerpohl JJ, Strehl D. How psychiatry journals support the unbiased translation of clinical research: a cross-sectional study of editorial policies. *PLoS One* 2013;8:e75995.
60. Rowbotham MC. The case for publishing ‘negative’ clinical trials. *Pain* 2009;146:225–226.

Neurology®

How transparent are migraine clinical trials?: Repository of Registered Migraine Trials (RReMiT)

Faustine L. Dufka, Robert H. Dworkin and Michael C. Rowbotham
Neurology 2014;83;1372-1381 Published Online before print September 5, 2014
DOI 10.1212/WNL.0000000000000866

This information is current as of September 5, 2014

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/83/15/1372.full
Supplementary Material	Supplementary material can be found at: http://n.neurology.org/content/suppl/2017/08/07/WNL.0000000000000866.DC1
References	This article cites 53 articles, 10 of which you can access for free at: http://n.neurology.org/content/83/15/1372.full#ref-list-1
Citations	This article has been cited by 1 HighWire-hosted articles: http://n.neurology.org/content/83/15/1372.full##otherarticles
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): All Clinical trials http://n.neurology.org/cgi/collection/all_clinical_trials Migraine http://n.neurology.org/cgi/collection/migraine
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2014 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.